Search

Your search keyword '"Blyuss, Oleg"' showing total 4 results
Start Over Author "Blyuss, Oleg" Database OAIster
4 results on '"Blyuss, Oleg"'

1. Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study.

Author

Channon-Wells, Samuel, Channon-Wells, Samuel, Vito, Ortensia, McArdle, Andrew J, Seaby, Eleanor G, Patel, Harsita, Shah, Priyen, Pazukhina, Ekaterina, Wilson, Clare, Broderick, Claire, D'Souza, Giselle, Keren, Ilana, Nijman, Ruud G, Tremoulet, Adriana, Munblit, Daniel, Ulloa-Gutierrez, Rolando, Carter, Michael J, Ramnarayan, Padmanabhan, De, Tisham, Hoggart, Clive, Whittaker, Elizabeth, Herberg, Jethro A, Kaforou, Myrsini, Cunnington, Aubrey J, Blyuss, Oleg, Levin, Michael, Best Available Treatment Study (BATS) consortium, Channon-Wells, Samuel, Channon-Wells, Samuel, Vito, Ortensia, McArdle, Andrew J, Seaby, Eleanor G, Patel, Harsita, Shah, Priyen, Pazukhina, Ekaterina, Wilson, Clare, Broderick, Claire, D'Souza, Giselle, Keren, Ilana, Nijman, Ruud G, Tremoulet, Adriana, Munblit, Daniel, Ulloa-Gutierrez, Rolando, Carter, Michael J, Ramnarayan, Padmanabhan, De, Tisham, Hoggart, Clive, Whittaker, Elizabeth, Herberg, Jethro A, Kaforou, Myrsini, Cunnington, Aubrey J, Blyuss, Oleg, Levin, Michael, and Best Available Treatment Study (BATS) consortium

Abstract

BackgroundMultisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition associated with SARS-CoV-2 infection, has emerged as a serious illness in children worldwide. Immunoglobulin or glucocorticoids, or both, are currently recommended treatments.MethodsThe Best Available Treatment Study evaluated immunomodulatory treatments for MIS-C in an international observational cohort. Analysis of the first 614 patients was previously reported. In this propensity-weighted cohort study, clinical and outcome data from children with suspected or proven MIS-C were collected onto a web-based Research Electronic Data Capture database. After excluding neonates and incomplete or duplicate records, inverse probability weighting was used to compare primary treatments with intravenous immunoglobulin, intravenous immunoglobulin plus glucocorticoids, or glucocorticoids alone, using intravenous immunoglobulin as the reference treatment. Primary outcomes were a composite of inotropic or ventilator support from the second day after treatment initiation, or death, and time to improvement on an ordinal clinical severity scale. Secondary outcomes included treatment escalation, clinical deterioration, fever, and coronary artery aneurysm occurrence and resolution. This study is registered with the ISRCTN registry, ISRCTN69546370.FindingsWe enrolled 2101 children (aged 0 months to 19 years) with clinically diagnosed MIS-C from 39 countries between June 14, 2020, and April 25, 2022, and, following exclusions, 2009 patients were included for analysis (median age 8·0 years [IQR 4·2-11·4], 1191 [59·3%] male and 818 [40·7%] female, and 825 [41·1%] White). 680 (33·8%) patients received primary treatment with intravenous immunoglobulin, 698 (34·7%) with intravenous immunoglobulin plus glucocorticoids, 487 (24·2%) with glucocorticoids alone; 59 (2·9%) patients received other combinations, including biologicals, and 85 (4·2%) patients received no immunomodulators. There were no signi

Published
2023

2. Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study

Author

Channon-Wells, Samuel, Vito, Ortensia, McArdle, Andrew J, Seaby, Eleanor G, Patel, Harsita, Shah, Priyen; https://orcid.org/0000-0001-9164-8862, Pazukhina, Ekaterina, Wilson, Clare, Broderick, Claire, D'Souza, Giselle, Keren, Ilana, Nijman, Ruud G, Tremoulet, Adriana, Munblit, Daniel, Ulloa-Gutierrez, Rolando; https://orcid.org/0000-0002-9157-9227, Carter, Michael J, Ramnarayan, Padmanabhan, De, Tisham, Hoggart, Clive, Whittaker, Elizabeth, Herberg, Jethro A; https://orcid.org/0000-0001-6941-6491, Kaforou, Myrsini, Cunnington, Aubrey J; https://orcid.org/0000-0002-1305-3529, Blyuss, Oleg, Levin, Michael, Best Available Treatment Study (BATS) consortium, et al, Trück, Johannes; https://orcid.org/0000-0002-0418-7381, Channon-Wells, Samuel, Vito, Ortensia, McArdle, Andrew J, Seaby, Eleanor G, Patel, Harsita, Shah, Priyen; https://orcid.org/0000-0001-9164-8862, Pazukhina, Ekaterina, Wilson, Clare, Broderick, Claire, D'Souza, Giselle, Keren, Ilana, Nijman, Ruud G, Tremoulet, Adriana, Munblit, Daniel, Ulloa-Gutierrez, Rolando; https://orcid.org/0000-0002-9157-9227, Carter, Michael J, Ramnarayan, Padmanabhan, De, Tisham, Hoggart, Clive, Whittaker, Elizabeth, Herberg, Jethro A; https://orcid.org/0000-0001-6941-6491, Kaforou, Myrsini, Cunnington, Aubrey J; https://orcid.org/0000-0002-1305-3529, Blyuss, Oleg, Levin, Michael, Best Available Treatment Study (BATS) consortium, et al, and Trück, Johannes; https://orcid.org/0000-0002-0418-7381

Abstract

Background: Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition associated with SARS-CoV-2 infection, has emerged as a serious illness in children worldwide. Immunoglobulin or glucocorticoids, or both, are currently recommended treatments. Methods: The Best Available Treatment Study evaluated immunomodulatory treatments for MIS-C in an international observational cohort. Analysis of the first 614 patients was previously reported. In this propensity-weighted cohort study, clinical and outcome data from children with suspected or proven MIS-C were collected onto a web-based Research Electronic Data Capture database. After excluding neonates and incomplete or duplicate records, inverse probability weighting was used to compare primary treatments with intravenous immunoglobulin, intravenous immunoglobulin plus glucocorticoids, or glucocorticoids alone, using intravenous immunoglobulin as the reference treatment. Primary outcomes were a composite of inotropic or ventilator support from the second day after treatment initiation, or death, and time to improvement on an ordinal clinical severity scale. Secondary outcomes included treatment escalation, clinical deterioration, fever, and coronary artery aneurysm occurrence and resolution. This study is registered with the ISRCTN registry, ISRCTN69546370. Findings: We enrolled 2101 children (aged 0 months to 19 years) with clinically diagnosed MIS-C from 39 countries between June 14, 2020, and April 25, 2022, and, following exclusions, 2009 patients were included for analysis (median age 8·0 years [IQR 4·2-11·4], 1191 [59·3%] male and 818 [40·7%] female, and 825 [41·1%] White). 680 (33·8%) patients received primary treatment with intravenous immunoglobulin, 698 (34·7%) with intravenous immunoglobulin plus glucocorticoids, 487 (24·2%) with glucocorticoids alone; 59 (2·9%) patients received other combinations, including biologicals, and 85 (4·2%) patients received no immunomodulators. There were

Published
2023

3. A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021

Author

Wulf Hanson, Sarah, Abbafati, Cristiana, Aerts, Joachim G, Al-Aly, Ziyad, Ashbaugh, Charlie, Ballouz, Tala, Blyuss, Oleg, Bobkova, Polina, Bonsel, Gouke, Borzakova, Svetlana, Buonsenso, Danilo, Butnaru, Denis, Carter, Austin, Chu, Helen, De Rose, Cristina, Diab, Mohamed Mustafa, Ekbom, Emil, El Tantawi, Maha, Fomin, Victor, Frithiof, Robert, Gamirova, Aysylu, Glybochko, Petr V, Haagsma, Juanita A, Javanmard, Shaghayegh Haghjooy, Hamilton, Erin B, Harris, Gabrielle, Heijenbrok-Kal, Majanka H, Helbok, Raimund, Hellemons, Merel E, Hillus, David, Huijts, Susanne M, Hultström, Michael, Jassat, Waasila, Kurth, Florian, Larsson, Ing-Marie, Lipcsey, Miklós, Liu, Chelsea, Loflin, Callan D, Malinovschi, Andrei, Mao, Wenhui, Mazankova, Lyudmila, McCulloch, Denise, Menges, Dominik, Mohammadifard, Noushin, Munblit, Daniel, Nekliudov, Nikita A, Ogbuoji, Osondu, Osmanov, Ismail M, Peñalvo, José L, Petersen, Maria Skaalum, Puhan, Milo A, Rahman, Mujibur, Rass, Verena, Reinig, Nickolas, Ribbers, Gerard M, Ricchiuto, Antonia, Rubertsson, Sten, Samitova, Elmira, Sarrafzadegan, Nizal, Shikhaleva, Anastasia, Simpson, Kyle E, Sinatti, Dario, Soriano, Joan B, Spiridonova, Ekaterina, Steinbeis, Fridolin, Svistunov, Andrey A, Valentini, Piero, van de Water, Brittney J, van den Berg-Emons, Rita, Wallin, Ewa, Witzenrath, Martin, Wu, Yifan, Xu, Hanzhang, Zoller, Thomas, Adolph, Christopher, Albright, James, Amlag, Joanne O, Aravkin, Aleksandr Y, Bang-Jensen, Bree L, Bisignano, Catherine, Castellano, Rachel, Castro, Emma, Chakrabarti, Suman, Collins, James K, Dai, Xiaochen, Daoud, Farah, Dapper, Carolyn, Deen, Amanda, Duncan, Bruce B, Erickson, Megan, Ewald, Samuel B, Ferrari, Alize J, Flaxman, Abraham D, Fullman, Nancy, Gamkrelidze, Amiran, Giles, John R, Guo, Gaorui, Hay, Simon I, He, Jiawei, Helak, Monika, Hulland, Erin N, Kereselidze, Maia, Krohn, Kris J, Lazzar-Atwood, Alice, Lindstrom, Akiaja, Lozano, Rafael, Magistro, Beatrice, Malta, Deborah Carvalho, Månsson, Johan, Mantilla Herrera, Ana M, Mokdad, Ali H, Monasta, Lorenzo, Nomura, Shuhei, Pasovic, Maja, Pigott, David M, Reiner, Robert C, Reinke, Grace, Ribeiro, Antonio Luiz P, Santomauro, Damian Francesco, Sholokhov, Aleksei, Spurlock, Emma Elizabeth, Walcott, Rebecca, Walker, Ally, Wiysonge, Charles Shey, Zheng, Peng, Bettger, Janet Prvu, Murray, Christopher Jl, Vos, Theo, Wulf Hanson, Sarah, Abbafati, Cristiana, Aerts, Joachim G, Al-Aly, Ziyad, Ashbaugh, Charlie, Ballouz, Tala, Blyuss, Oleg, Bobkova, Polina, Bonsel, Gouke, Borzakova, Svetlana, Buonsenso, Danilo, Butnaru, Denis, Carter, Austin, Chu, Helen, De Rose, Cristina, Diab, Mohamed Mustafa, Ekbom, Emil, El Tantawi, Maha, Fomin, Victor, Frithiof, Robert, Gamirova, Aysylu, Glybochko, Petr V, Haagsma, Juanita A, Javanmard, Shaghayegh Haghjooy, Hamilton, Erin B, Harris, Gabrielle, Heijenbrok-Kal, Majanka H, Helbok, Raimund, Hellemons, Merel E, Hillus, David, Huijts, Susanne M, Hultström, Michael, Jassat, Waasila, Kurth, Florian, Larsson, Ing-Marie, Lipcsey, Miklós, Liu, Chelsea, Loflin, Callan D, Malinovschi, Andrei, Mao, Wenhui, Mazankova, Lyudmila, McCulloch, Denise, Menges, Dominik, Mohammadifard, Noushin, Munblit, Daniel, Nekliudov, Nikita A, Ogbuoji, Osondu, Osmanov, Ismail M, Peñalvo, José L, Petersen, Maria Skaalum, Puhan, Milo A, Rahman, Mujibur, Rass, Verena, Reinig, Nickolas, Ribbers, Gerard M, Ricchiuto, Antonia, Rubertsson, Sten, Samitova, Elmira, Sarrafzadegan, Nizal, Shikhaleva, Anastasia, Simpson, Kyle E, Sinatti, Dario, Soriano, Joan B, Spiridonova, Ekaterina, Steinbeis, Fridolin, Svistunov, Andrey A, Valentini, Piero, van de Water, Brittney J, van den Berg-Emons, Rita, Wallin, Ewa, Witzenrath, Martin, Wu, Yifan, Xu, Hanzhang, Zoller, Thomas, Adolph, Christopher, Albright, James, Amlag, Joanne O, Aravkin, Aleksandr Y, Bang-Jensen, Bree L, Bisignano, Catherine, Castellano, Rachel, Castro, Emma, Chakrabarti, Suman, Collins, James K, Dai, Xiaochen, Daoud, Farah, Dapper, Carolyn, Deen, Amanda, Duncan, Bruce B, Erickson, Megan, Ewald, Samuel B, Ferrari, Alize J, Flaxman, Abraham D, Fullman, Nancy, Gamkrelidze, Amiran, Giles, John R, Guo, Gaorui, Hay, Simon I, He, Jiawei, Helak, Monika, Hulland, Erin N, Kereselidze, Maia, Krohn, Kris J, Lazzar-Atwood, Alice, Lindstrom, Akiaja, Lozano, Rafael, Magistro, Beatrice, Malta, Deborah Carvalho, Månsson, Johan, Mantilla Herrera, Ana M, Mokdad, Ali H, Monasta, Lorenzo, Nomura, Shuhei, Pasovic, Maja, Pigott, David M, Reiner, Robert C, Reinke, Grace, Ribeiro, Antonio Luiz P, Santomauro, Damian Francesco, Sholokhov, Aleksei, Spurlock, Emma Elizabeth, Walcott, Rebecca, Walker, Ally, Wiysonge, Charles Shey, Zheng, Peng, Bettger, Janet Prvu, Murray, Christopher Jl, and Vos, Theo

Abstract

Importance: While much of the attention on the COVID-19 pandemic was directed at the daily counts of cases and those with serious disease overwhelming health services, increasingly, reports have appeared of people who experience debilitating symptoms after the initial infection. This is popularly known as long COVID. Objective: To estimate by country and territory of the number of patients affected by long COVID in 2020 and 2021, the severity of their symptoms and expected pattern of recovery. Design: We jointly analyzed ten ongoing cohort studies in ten countries for the occurrence of three major symptom clusters of long COVID among representative COVID cases. The defining symptoms of the three clusters (fatigue, cognitive problems, and shortness of breath) are explicitly mentioned in the WHO clinical case definition. For incidence of long COVID, we adopted the minimum duration after infection of three months from the WHO case definition. We pooled data from the contributing studies, two large medical record databases in the United States, and findings from 44 published studies using a Bayesian meta-regression tool. We separately estimated occurrence and pattern of recovery in patients with milder acute infections and those hospitalized. We estimated the incidence and prevalence of long COVID globally and by country in 2020 and 2021 as well as the severity-weighted prevalence using disability weights from the Global Burden of Disease study. Results: Analyses are based on detailed information for 1906 community infections and 10526 hospitalized patients from the ten collaborating cohorts, three of which included children. We added published data on 37262 community infections and 9540 hospitalized patients as well as ICD-coded medical record data concerning 1.3 million infections. Globally, in 2020 and 2021, 144.7 million (95% uncertainty interval [UI] 54.8-312.9) people suffered from any of the three symptom clusters of long COVID. This corresponds to 3.69% (1.38-7.

Published
2022
Full Text
View/download PDF

4. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021

Author

Wulf Hanson, Sarah, Abbafati, Cristiana, Aerts, Joachim G, Al-Aly, Ziyad, Ashbaugh, Charlie, Ballouz, Tala, Blyuss, Oleg, Bobkova, Polina, Bonsel, Gouke, Borzakova, Svetlana, Buonsenso, Danilo, Butnaru, Denis, Carter, Austin, Chu, Helen, De Rose, Cristina, Diab, Mohamed Mustafa, Ekbom, Emil, El Tantawi, Maha, Fomin, Victor, Frithiof, Robert, Gamirova, Aysylu, Glybochko, Petr V, Haagsma, Juanita A, Haghjooy Javanmard, Shaghayegh, Hamilton, Erin B, Harris, Gabrielle, Heijenbrok-Kal, Majanka H, Helbok, Raimund, Hellemons, Merel E, Hillus, David, Huijts, Susanne M, Hultström, Michael, Jassat, Waasila, Kurth, Florian, Larsson, Ing-Marie, Lipcsey, Miklós, Liu, Chelsea, Loflin, Callan D, Malinovschi, Andrei, Mao, Wenhui, Mazankova, Lyudmila, McCulloch, Denise, Menges, Dominik, Mohammadifard, Noushin, Munblit, Daniel, Nekliudov, Nikita A, Ogbuoji, Osondu, Osmanov, Ismail M, Peñalvo, José L, Petersen, Maria Skaalum, Puhan, Milo A, Rahman, Mujibur, Rass, Verena, Reinig, Nickolas, Ribbers, Gerard M, Ricchiuto, Antonia, Rubertsson, Sten, Samitova, Elmira, Sarrafzadegan, Nizal, Shikhaleva, Anastasia, Simpson, Kyle E, Sinatti, Dario, Soriano, Joan B, Spiridonova, Ekaterina, Steinbeis, Fridolin, Svistunov, Andrey A, Valentini, Piero, van de Water, Brittney J, van den Berg-Emons, Rita, Wallin, Ewa, Witzenrath, Martin, Wu, Yifan, Xu, Hanzhang, Zoller, Thomas, Adolph, Christopher, Albright, James, Amlag, Joanne O, Aravkin, Aleksandr Y, Bang-Jensen, Bree L, Bisignano, Catherine, Castellano, Rachel, Castro, Emma, Chakrabarti, Suman, Collins, James K, Dai, Xiaochen, Daoud, Farah, Dapper, Carolyn, Deen, Amanda, Duncan, Bruce B, Erickson, Megan, Ewald, Samuel B, Ferrari, Alize J, Flaxman, Abraham D, Fullman, Nancy, Gamkrelidze, Amiran, Giles, John R, Guo, Gaorui, Hay, Simon I, He, Jiawei, Helak, Monika, Hulland, Erin N, Kereselidze, Maia, Krohn, Kris J, Lazzar-Atwood, Alice, Lindstrom, Akiaja, Lozano, Rafael, Malta, Deborah Carvalho, Månsson, Johan, Mantilla Herrera, Ana M, Mokdad, Ali H, Monasta, Lorenzo, Nomura, Shuhei, Pasovic, Maja, Pigott, David M, Reiner, Robert C, Reinke, Grace, Ribeiro, Antonio Luiz P, Santomauro, Damian Francesco, Sholokhov, Aleksei, Spurlock, Emma Elizabeth, Walcott, Rebecca, Walker, Ally, Wiysonge, Charles Shey, Zheng, Peng, Bettger, Janet Prvu, Murray, Christopher J L, Vos, Theo, Wulf Hanson, Sarah, Abbafati, Cristiana, Aerts, Joachim G, Al-Aly, Ziyad, Ashbaugh, Charlie, Ballouz, Tala, Blyuss, Oleg, Bobkova, Polina, Bonsel, Gouke, Borzakova, Svetlana, Buonsenso, Danilo, Butnaru, Denis, Carter, Austin, Chu, Helen, De Rose, Cristina, Diab, Mohamed Mustafa, Ekbom, Emil, El Tantawi, Maha, Fomin, Victor, Frithiof, Robert, Gamirova, Aysylu, Glybochko, Petr V, Haagsma, Juanita A, Haghjooy Javanmard, Shaghayegh, Hamilton, Erin B, Harris, Gabrielle, Heijenbrok-Kal, Majanka H, Helbok, Raimund, Hellemons, Merel E, Hillus, David, Huijts, Susanne M, Hultström, Michael, Jassat, Waasila, Kurth, Florian, Larsson, Ing-Marie, Lipcsey, Miklós, Liu, Chelsea, Loflin, Callan D, Malinovschi, Andrei, Mao, Wenhui, Mazankova, Lyudmila, McCulloch, Denise, Menges, Dominik, Mohammadifard, Noushin, Munblit, Daniel, Nekliudov, Nikita A, Ogbuoji, Osondu, Osmanov, Ismail M, Peñalvo, José L, Petersen, Maria Skaalum, Puhan, Milo A, Rahman, Mujibur, Rass, Verena, Reinig, Nickolas, Ribbers, Gerard M, Ricchiuto, Antonia, Rubertsson, Sten, Samitova, Elmira, Sarrafzadegan, Nizal, Shikhaleva, Anastasia, Simpson, Kyle E, Sinatti, Dario, Soriano, Joan B, Spiridonova, Ekaterina, Steinbeis, Fridolin, Svistunov, Andrey A, Valentini, Piero, van de Water, Brittney J, van den Berg-Emons, Rita, Wallin, Ewa, Witzenrath, Martin, Wu, Yifan, Xu, Hanzhang, Zoller, Thomas, Adolph, Christopher, Albright, James, Amlag, Joanne O, Aravkin, Aleksandr Y, Bang-Jensen, Bree L, Bisignano, Catherine, Castellano, Rachel, Castro, Emma, Chakrabarti, Suman, Collins, James K, Dai, Xiaochen, Daoud, Farah, Dapper, Carolyn, Deen, Amanda, Duncan, Bruce B, Erickson, Megan, Ewald, Samuel B, Ferrari, Alize J, Flaxman, Abraham D, Fullman, Nancy, Gamkrelidze, Amiran, Giles, John R, Guo, Gaorui, Hay, Simon I, He, Jiawei, Helak, Monika, Hulland, Erin N, Kereselidze, Maia, Krohn, Kris J, Lazzar-Atwood, Alice, Lindstrom, Akiaja, Lozano, Rafael, Malta, Deborah Carvalho, Månsson, Johan, Mantilla Herrera, Ana M, Mokdad, Ali H, Monasta, Lorenzo, Nomura, Shuhei, Pasovic, Maja, Pigott, David M, Reiner, Robert C, Reinke, Grace, Ribeiro, Antonio Luiz P, Santomauro, Damian Francesco, Sholokhov, Aleksei, Spurlock, Emma Elizabeth, Walcott, Rebecca, Walker, Ally, Wiysonge, Charles Shey, Zheng, Peng, Bettger, Janet Prvu, Murray, Christopher J L, and Vos, Theo

Abstract

IMPORTANCE: Some individuals experience persistent symptoms after initial symptomatic SARS-CoV-2 infection (often referred to as Long COVID). OBJECTIVE: To estimate the proportion of males and females with COVID-19, younger or older than 20 years of age, who had Long COVID symptoms in 2020 and 2021 and their Long COVID symptom duration. DESIGN, SETTING, AND PARTICIPANTS: Bayesian meta-regression and pooling of 54 studies and 2 medical record databases with data for 1.2 million individuals (from 22 countries) who had symptomatic SARS-CoV-2 infection. Of the 54 studies, 44 were published and 10 were collaborating cohorts (conducted in Austria, the Faroe Islands, Germany, Iran, Italy, the Netherlands, Russia, Sweden, Switzerland, and the US). The participant data were derived from the 44 published studies (10 501 hospitalized individuals and 42 891 nonhospitalized individuals), the 10 collaborating cohort studies (10 526 and 1906), and the 2 US electronic medical record databases (250 928 and 846 046). Data collection spanned March 2020 to January 2022. EXPOSURES: Symptomatic SARS-CoV-2 infection. MAIN OUTCOMES AND MEASURES: Proportion of individuals with at least 1 of the 3 self-reported Long COVID symptom clusters (persistent fatigue with bodily pain or mood swings; cognitive problems; or ongoing respiratory problems) 3 months after SARS-CoV-2 infection in 2020 and 2021, estimated separately for hospitalized and nonhospitalized individuals aged 20 years or older by sex and for both sexes of nonhospitalized individuals younger than 20 years of age. RESULTS: A total of 1.2 million individuals who had symptomatic SARS-CoV-2 infection were included (mean age, 4-66 years; males, 26%-88%). In the modeled estimates, 6.2% (95% uncertainty interval [UI], 2.4%-13.3%) of individuals who had symptomatic SARS-CoV-2 infection experienced at least 1 of the 3 Long COVID symptom clusters in 2020 and 2021, including 3.2% (95% UI, 0.6%-10.0%) for persistent fatigue with bodily pain or

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results